Will MetLife Egypt and AXA Egypt cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Fabhalta is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by EDA?

The EDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; EDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Egyptian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Egyptian Medical Syndicate and the EDA verifies the active license; the EDA application records both the prescribing physician and the dispensing facility.

Can I receive Fabhalta at home?

The dispensing facility must be Egyptian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 18,000 to 19,500 per month. Delivered quote within 24h.Get my quote

Fabhalta access in Egypt: the EDA named-patient pathway

How patients in the Arab Republic of Egypt legally obtain Fabhalta (iptacopan) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Egypt access Fabhalta (iptacopan) for paroxysmal nocturnal hemoglobinuria (PNH) in adults, IgA nephropathy in adults at risk of rapid disease progression, and complement-3-glomerulopathy (C3G) through the EDA named-patient pathway, an Egyptian Drug Authority-administered mechanism that allows an Egyptian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in EGP.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Fabhalta reaches patients in Egypt

Fabhalta (iptacopan, oral selective Factor B inhibitor of the alternative complement pathway, FDA-approved December 2023 for paroxysmal nocturnal haemoglobinuria, August 2024 for IgA nephropathy in adults at risk of rapid disease progression, March 2025 for complement-3 glomerulopathy) is not registered with the EDA and is not visible on eservices.edaegypt.gov.eg/EDASearch/SearchRegDrugs as of 2026-05-31. Egyptian patients access Fabhalta through Personal Importation of Unregistered Medicines via the EDA Central Administration for Pharmaceutical Affairs under Pharmacy Practice Law No. 127 of 1955 read with Health Minister Decree No. 296 of 2009 and Law No. 151 of 2019. The Fabhalta-specific clinical justification depends on indication: for PNH, GPI-anchor-deficient clone confirmation by flow cytometry plus haemolysis markers (LDH at least 1.5x ULN); for IgAN, biopsy-confirmed IgA nephropathy with persistent proteinuria of 1.5 g per day or greater on optimised RAS blockade; for C3G, biopsy-confirmed C3 glomerulopathy. Critical: vaccination against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B at least 2 weeks before initiation per the FDA Boxed Warning; the vaccination certificate is required in the application package. The supporting medical report must be stamped by the treating Egyptian-licensed nephrologist or haematologist. EDA processing is 1 to 3 weeks when documentation is complete.

Where Fabhalta is dispensed in Egypt

Fabhalta has two specialty axes (PNH on haematology; IgAN and C3G on nephrology). For PNH the relevant Egyptian tertiary haematology nodes are the NCI Cairo University Department of Haematology in Cairo at nci.cu.edu.eg, Cairo University Hospitals (Kasr Al-Ainy) Department of Internal Medicine and Haematology, Ain Shams University Hospitals Department of Internal Medicine and Haematology, and Alexandria University Hospitals Department of Haematology. For IgAN and C3G the relevant Egyptian tertiary nephrology nodes are Cairo University Hospitals (Kasr Al-Ainy) Nephrology service, the National Institute of Nephrology and Urology, Ain Shams University Hospitals Department of Internal Medicine and Nephrology, Alexandria University Hospitals Department of Nephrology, Mansoura University Hospitals Urology and Nephrology Center (a globally-recognised renal-disease and transplant centre), and the Mansoura University Hospitals Renal Pathology service which is the most-frequent reference for IgAN biopsy interpretation in Egypt. Mansoura University Hospitals' nephrology programme has historically published renal-disease epidemiology data and is the most-frequent reference centre for biopsy-confirmed glomerular-disease cohorts including IgAN and C3G. The vaccination-before-initiation step is co-managed with the same tertiary centre's infectious-diseases or vaccination clinic.

What Fabhalta costs in Egypt

The US reference WAC for Fabhalta is approximately USD 19,000 to USD 21,000 per 30-day supply at the labelled dose of 200 mg twice daily per Novartis disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Annual WAC at the labelled dose runs USD 225,000 to USD 250,000. No public local-currency EGP benchmark for Fabhalta is observed on the EDA database or via UPA at upa.gov.eg as of 2026-05-31; do not estimate. Price snapshot: 2026-05-31. The EGP-to-USD spot rate from the Central Bank of Egypt on the date of any quote should be footnoted, given EGP volatility. Cost layers: ambient-temperature international logistics into Egypt (low to mid four-figure USD; Fabhalta is a stable oral capsule), EDA permit and customs (nominal), the dispensing hospital's nephrology or haematology consultation and surveillance fees (urine PCR, eGFR, LDH, complement assay schedule), pre-treatment vaccination cost (non-trivial when administered as a complete meningococcal-pneumococcal-Hib panel), and Reserve Meds concierge fee itemised separately.

Funding and access barriers for Fabhalta in Egypt

PNH is rare (incidence approximately 1.3 per million per year); IgAN is the most common primary glomerulonephritis globally. Egyptian published biopsy series from Mansoura and Cairo University place IgAN among the leading primary glomerulonephritides in adult Egyptian renal biopsies, driving a meaningful Fabhalta-eligible cohort. C3G is rare. Public-sector funding: UHIA at uhia.gov.eg phased rollout in implementation governorates includes nephrology services but has not adjudicated iptacopan through its UPA-co-developed HTA process. Treatment at State Expense (Nafaqat Ala Al-Dawla) adjudicates high-cost rare-disease drug case-by-case; iptacopan approval via this route is not a documented precedent at the price point. Children's Cancer Hospital Egypt 57357 is paediatric-oncology-focused and does not apply. Major private insurers (MetLife Egypt, AXA Egypt, Bupa Egypt, Allianz Egypt, Misr Insurance, Globemed Egypt TPA, Med Net) typically exclude or sub-limit unregistered named-patient imports; corporate group policies with step-therapy documentation may include. The Boxed Warning vaccination requirement is an operational gate that drives the EDA submission timeline. Out-of-pocket plus pharma compassionate-access (Novartis Egypt patient-support programme operates case-by-case for selected complement-mediated diseases) is the documented funding pattern.

Recent regulatory and access news for Fabhalta

FDA expanded the Fabhalta label (March 2025) to C3 glomerulopathy in adults, the first FDA-approved therapy for C3G; the approval is referenced at accessdata.fda.gov/scripts/cder/daf. EMA (CHMP) issued a positive opinion for iptacopan in IgAN in 2024 with subsequent European Commission approval. Novartis launched an iptacopan expanded-access programme in C3G in selected regions in 2025. The EDA News feed at edaegypt.gov.eg/en/news does not show a Fabhalta-specific bulletin over the last 12 months. UHIA and UPA continue the phased UHI rollout in Egyptian governorates; each new phase modifies the payer mix for new-drug access.

Where Reserve Meds fits in Fabhalta cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace EDA, and we do not replace your dispensing pharmacy. For Fabhalta specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Egypt, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Fabhalta case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the EDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Fabhalta's oral once-twice-daily dosing changes the PNH treatment paradigm relative to infused C5 inhibitors; named-patient files document the meningococcal vaccination status mandated by the FDA label. Egyptian specialty referral concentrates these cases at the National Cancer Institute and Ain Shams networks.

Next step

If your Egyptian physician has prescribed Fabhalta and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Fabhalta case Or message us on WhatsApp